Nuvo Research Inc., of Mississauga, Ontario, said it completed enrollment in a phase II trial of WF10 in patients with refractory allergic rhinitis. The 16-week, randomized, double-blind, placebo-controlled study will assess the efficacy, safety and tolerability of a regimen of five infusions of either WF10 or its main constituents (sodium chlorite and sodium chlorate) relative to saline control in patients with multiple airborne allergies who suffer from moderate to severe allergic rhinitis.